Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the stock market today, but that was little changed from when shares were halted at 542.01 for much of the afternoon. The FDA announced approval of Praluent for patients with a genetic predisposition to high